PMID- 19173749
OWN - NLM
STAT- MEDLINE
DCOM- 20090318
LR  - 20211020
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 8
DP  - 2009 Jan 28
TI  - Long-term effects of peroxisome proliferator-activated receptor ligand 
      bezafibrate on N-terminal pro-B type natriuretic peptide in patients with 
      advanced functional capacity impairment.
PG  - 5
LID - 10.1186/1475-2840-8-5 [doi]
AB  - BACKGROUND: The effects of pan-peroxisome proliferator-activated receptor (PPAR) 
      ligand bezafibrate on N-terminal pro-B type natriuretic peptide (ProBNP) level in 
      patients with coronary artery disease (CAD) is unknown. The current study aimed 
      to investigate the long-term effects of bezafibrate on ProBNP level in patients 
      with pre-existing CAD and advanced functional capacity impairment. METHODS: 
      Metabolic and inflammatory parameters were analyzed from stored frozen serum 
      samples obtained from 108 patients enrolled in the Bezafibrate Infarction 
      Prevention (BIP) Study. They presented with New York Heart Association (NYHA) 
      functional class III, comprising 58 patients in the bezafibrate group and 50 in 
      the placebo groups, and completed a 2-year prospective, double-blind, 
      placebo-controlled follow-up. RESULTS: During follow-up ProBNP level did not 
      change significantly in the placebo group, whereas it increased slightly in the 
      bezafibrate group, which was older and with lower baseline ProBNP values. No 
      significant differences between the groups were found for ProBNP levels after 2 
      year of follow-up. Analysis-of-covariance (ANCOVA) -taking into account age and 
      baseline ProBNP level- showed that bezafibrate was not associated with 
      longitudinal ProBNP changes during the follow-up period (p = 0.3). CONCLUSION: 
      Long-term treatment by bezafibrate was not associated with longitudinal ProBNP 
      changes in patients with pre-existing CAD and advanced functional capacity 
      impairment.
FAU - Node, Koichi
AU  - Node K
AD  - Department of Cardiovascular and Renal Medicine, Saga University Faculty of 
      Medicine, Saga, Japan. node@cc.saga-u.ac.jp
FAU - Inoue, Teruo
AU  - Inoue T
FAU - Boyko, Valentin
AU  - Boyko V
FAU - Goldberg, Ilan
AU  - Goldberg I
FAU - Fisman, Enrique Z
AU  - Fisman EZ
FAU - Adler, Yehuda
AU  - Adler Y
FAU - Schwammenthal, Ehud
AU  - Schwammenthal E
FAU - Matas, Zipora
AU  - Matas Z
FAU - Behar, Solomon
AU  - Behar S
FAU - Tenenbaum, Alexander
AU  - Tenenbaum A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090128
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (PPAR gamma)
RN  - 0 (Peptide Fragments)
RN  - 0 (Peroxisome Proliferator-Activated Receptors)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - Y9449Q51XH (Bezafibrate)
SB  - IM
MH  - Aged
MH  - Bezafibrate/adverse effects/*pharmacology/therapeutic use
MH  - Coronary Artery Disease/*blood/complications/drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*blood/etiology
MH  - Humans
MH  - Hypolipidemic Agents/adverse effects/*pharmacology/therapeutic use
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/blood/drug therapy/etiology
MH  - Natriuretic Peptide, Brain/*blood
MH  - PPAR gamma/agonists/physiology
MH  - Peptide Fragments/*blood
MH  - Peroxisome Proliferator-Activated Receptors/*agonists
MH  - Randomized Controlled Trials as Topic/statistics & numerical data
MH  - Severity of Illness Index
PMC - PMC2645368
EDAT- 2009/01/29 09:00
MHDA- 2009/03/19 09:00
PMCR- 2009/01/28
CRDT- 2009/01/29 09:00
PHST- 2008/12/04 00:00 [received]
PHST- 2009/01/28 00:00 [accepted]
PHST- 2009/01/29 09:00 [entrez]
PHST- 2009/01/29 09:00 [pubmed]
PHST- 2009/03/19 09:00 [medline]
PHST- 2009/01/28 00:00 [pmc-release]
AID - 1475-2840-8-5 [pii]
AID - 10.1186/1475-2840-8-5 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2009 Jan 28;8:5. doi: 10.1186/1475-2840-8-5.